Roivant Sciences (ROIV) Announces Q1 2025 Business Update

Roivant Sciences Ltd (NASDAQ:ROIV) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 11, Roivant Sciences Ltd (NASDAQ:ROIV) reported its financial and business update for the fiscal first quarter of 2025.

The company reported several positive business updates, including the Brepocitinib VALOR Phase 3 study for dermatomyositis remaining on track for topline data in the second half of 2025. Moreover, Immunovant, which is a subsidiary of Roivant Sciences Ltd (NASDAQ:ROIV), started new registrational trials for IMVT-1402 in Graves’ disease and Sjögren’s disease, with all other trials progressing well.

Roivant Sciences (ROIV) Announces Q1 2025 Business Update

The company had $4.5 billion in cash and marketable securities as of June 30, 2025. Management believes this supports the cash runway into profitability.

Roivant Sciences Ltd (NASDAQ:ROIV) is a biopharmaceutical company that develops and commercializes innovative medicines by building focused subsidiary companies called Vants.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.